Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zenas Stages US IPO for Autoimmune Candidate

publication date: Sep 23, 2024

Zenas BioPharma raised $259 million in a rare US biopharma IPO. The offering was priced at $17 per share, the middle of the expected range. The company will use the funds to complete late-stage development of its lead product, obexelimab. Founded in 2019, Zenas was originally headquartered in Shanghai, but has now moved to the Boston area while maintaining a China presence. The Zenas IPO was one of three US biotech IPOs conducted on the same day, raising a total of $700 million and also raising biotech investor hopes that an IPO revival could be possible. More details....

Stock Symbol: (NSDQ: ZBIO)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here